EAU Edu Platform UROONCO

@EAU_Uroonco

The EAU Edu Platform for all healthcare professionals in uro-oncology. UROONCO is an initiative of the EAU in close collaboration with ESU and European Urology.

Europe
Vrijeme pridruživanja: ožujak 2014.

Tweetovi

Blokirali ste korisnika/cu @EAU_Uroonco

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @EAU_Uroonco

  1. proslijedio/la je Tweet

    3 urological cancers are among the top 10 most common cancers in Europe: Prostate, Bladder and Kidney. Every person matters. Every action counts. That is why we constantly update the EAUguidelines. ▶️

    Poništi
  2. Today is World Cancer Day. Share your reasons for specializing in treating genitourinary cancers by leaving a comment below.

    Poništi
  3. Poništi
  4. 2. velj
    Poništi
  5. 30. sij

    In this webcast, 3 real-life clinical cases were discussed on the contemporary key topics in (PN) from a surgical point of view. 👇

    Poništi
  6. 28. sij
    Poništi
  7. 26. sij
    Poništi
  8. proslijedio/la je Tweet
    18. sij

    Ready to launch a new and initiative . Soon online via 📹

    Prikaži ovu nit
    Poništi
  9. proslijedio/la je Tweet
    19. sij

    Last day at , right now friend brilliantly informing about important readings in

    Poništi
  10. 22. sij

    Deep-learning artificial intelligence systems performs similar to expert human pathologist in diagnosis and grading. Read more 👇

    Poništi
  11. proslijedio/la je Tweet
    19. sij
    Odgovor korisnicima i sljedećem broju korisnika:

    Happy to have made it to the list and share last position with See you at

    Poništi
  12. proslijedio/la je Tweet
    19. sij

    Time to stay goodbye Dublin, welcome back everyday practice. Thank you for excellent , congratulations to and the new board. Happy to be one of influencers, at least at the level

    , , i još njih 6
    Poništi
  13. proslijedio/la je Tweet
    18. sij

    RNU alone is insufficient in most patients said Perioperative systemic treatment should be proposed systematically

    Poništi
  14. 19. sij

    Prospective assessment of VI-RADS clinical impact sensitivity 91.9% in differentiating NMIBC from MIBC at initial TUR. In HR-NMIBC, 85% sensitivity in predicting MIBC at re-TUR. 👇

    Poništi
  15. 18. sij

    On developments in robotic surgery.

    Poništi
  16. 18. sij

    M Stuiver on management of lymphedema. Elaborate compression techniques.

    Poništi
  17. 18. sij
    Poništi
  18. 18. sij

    Next recurrent PCa after prostatectomy or radiotherapy

    Poništi
  19. 18. sij

    On the role of surgery in high risk PCa: How to predict which patients are cured by prostatectomy + PLND alone?

    Poništi
  20. proslijedio/la je Tweet
    17. sij

    starting the session during with a brilliant lecture on genomic and

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·